At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
MM-111drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
In Brief
A Phase 1 clinical trial evaluating MM-111 for Her2 Amplified Solid Tumors and Metastatic Breast Cancer. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
This study is an open-label Phase 1 trial of MM-111.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionMar 2012
TodayJul 2026
First PostedJun 3, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.1 years ago
Interventions
MM-111drug
For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV